Giredestrant, FDA-approved this week, uses a different companion blood test from every other oral ER drug for ESR1-mutated breast cancer. We compared all five labels. The test isn’t the only difference. lifesciencedaily.news/girede… #BreastCancer #FDA
32
New Post: Too Good to Be True: The Case for Honest Medical-AI Benchmarks lifesciencedaily.news/medica…
2
AriBio’s AR1001 met its Phase 3 primary objective in early Alzheimer’s, but only in the monotherapy group. Across all 1,535 patients it showed almost no difference from placebo.
Four more results here: lifesciencedaily.news/clinic… #ClinicalTrials #Alzheimers
5
New Post: Neladalkib vs Lorlatinib: How GSK’s New ALK Drug Compares lifesciencedaily.news/nelada…
21
New Post: The Synthetic Patient Problem: AI Risks Removing Patients from Healthcare lifesciencedaily.news/synthe…
2
Pfizer’s Starna licence is being reported at up to $2.6B. The cash committed upfront is $330M, for three in vivo CAR-T programmes that haven’t reached the clinic. We looked at what that actually buys. lifesciencedaily.news/pfizer… #InVivoCART #Autoimmunity
7
New Post: Treatment Escalation Is a Decision Pathway, Not a Single Choice lifesciencedaily.news/treatm…
2
New Post: Isomorphic Labs Clinical Trial: When Will Its AI-Designed Drugs Start? lifesciencedaily.news/isomor…
7
New Post: Weaker or Just Lighter? The Measurement GLP-1 Weight Loss Is Missing lifesciencedaily.news/weaker…
5
Treasury’s draft COINS Act biotech rule doesn’t name licensing as a covered transaction. Bills in Congress would. So where does that leave a China licence with an option or equity stake attached? lifesciencedaily.news/coins-… #Biotech #COINSAct
7
A compound that rescues neurons in a dish has passed one test. A contributed piece from Creative Biolabs on what a CNS screening hit still has to prove before anyone backs it. lifesciencedaily.news/cns-dr… #DrugDiscovery #ParkinsonsDisease
1
17
OLN324’s early data were measured against Vabysmo. Its registered Phase 3 trials include GOBI, against aflibercept, but as of 17 November no Phase 3 against Vabysmo could be confirmed. lifesciencedaily.news/oln324… #Ophthalmology #ClinicalTrials
9
J&J’s Ollin deal comes to about $3.3bn on paper, but $1.125bn of that rides on milestones whose triggers J&J hasn’t disclosed. Separately, Blackstone is paying J&J $750m to fund the Phase 3 programme. lifesciencedaily.news/ollin-… #BiotechDeals #Ophthalmology
7














